The combination therapy of Infergen® (interferon alfacon-1) plus Actimmune® (interferon gamma-1b) is effective in hard-to-treat patients with chronic Hepatitis C.
Presented December 17 at the HepDART meeting in Hawaii, the study involved 32 patients who had previously failed to show any significant reduction in viral load following 12 weeks of therapy with pegylated interferon-alpha 2 plus ribavirin.
According to the researchers, this group of nonresponders is typically considered to be one of the most difficult patient populations to treat.
After 12 weeks of therapy with Infergen and Actimmune, 38 percent of the participants had undetectable levels of virus in their blood, while 65 percent had at least a 2 log decline in viral load. No patients discontinued therapy.
"Treatment options for pegylated interferon-alpha 2 plus ribavirin nonresponders are very limited," said Dr. Carroll Leevy, of the New Jersey Medical Liver Center and Sammy Davis Jr. National Liver Center in Newark, N.J. "The data from this patient experience are encouraging, and this combination therapy may offer hope to patients who do not respond to standard interferon plus ribavirin therapy."
Other sources: InterMune